CRIS Current Research Information System

BARTOLETTI, DANIELA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 1.393
NA - Nord America 1.315
EU - Europa 780
AF - Africa 92
SA - Sud America 76
OC - Oceania 3
Totale 3.659
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.280
SG - Singapore 419
VN - Vietnam 349
CN - Cina 336
IT - Italia 148
DE - Germania 121
SE - Svezia 118
GB - Regno Unito 97
HK - Hong Kong 73
IN - India 70
FR - Francia 59
BR - Brasile 56
IE - Irlanda 45
RU - Federazione Russa 43
NL - Olanda 37
FI - Finlandia 36
CI - Costa d'Avorio 35
KR - Corea 34
TG - Togo 22
CA - Canada 20
JP - Giappone 18
ZA - Sudafrica 13
BD - Bangladesh 11
CH - Svizzera 11
ID - Indonesia 11
PL - Polonia 11
JO - Giordania 10
PH - Filippine 10
TH - Thailandia 10
BE - Belgio 9
TR - Turchia 9
TW - Taiwan 9
UA - Ucraina 9
AT - Austria 7
BG - Bulgaria 7
MX - Messico 7
AR - Argentina 5
CO - Colombia 5
EC - Ecuador 5
EE - Estonia 5
PK - Pakistan 5
NG - Nigeria 4
SA - Arabia Saudita 4
TN - Tunisia 4
AU - Australia 3
ET - Etiopia 3
HR - Croazia 3
IQ - Iraq 3
MA - Marocco 3
AE - Emirati Arabi Uniti 2
AZ - Azerbaigian 2
CZ - Repubblica Ceca 2
EG - Egitto 2
ES - Italia 2
JM - Giamaica 2
LT - Lituania 2
RO - Romania 2
UY - Uruguay 2
AL - Albania 1
AO - Angola 1
BB - Barbados 1
BS - Bahamas 1
CR - Costa Rica 1
CY - Cipro 1
DK - Danimarca 1
DZ - Algeria 1
GA - Gabon 1
GE - Georgia 1
GF - Guiana Francese 1
HU - Ungheria 1
KE - Kenya 1
KY - Cayman, isole 1
KZ - Kazakistan 1
LB - Libano 1
LV - Lettonia 1
MG - Madagascar 1
MK - Macedonia 1
MY - Malesia 1
NI - Nicaragua 1
NP - Nepal 1
PE - Perù 1
PY - Paraguay 1
RS - Serbia 1
SC - Seychelles 1
SY - Repubblica araba siriana 1
TT - Trinidad e Tobago 1
UZ - Uzbekistan 1
Totale 3.659
Salva come PNG Salva come JPEG
Città #
Singapore 311
Ashburn 182
Chandler 121
San Jose 103
Hanoi 89
Ho Chi Minh City 77
Southend 69
Hong Kong 66
Fairfield 64
Hefei 54
Santa Clara 54
Beijing 46
Dublin 45
Dallas 42
Los Angeles 38
Princeton 38
Abidjan 35
Dong Ket 32
Houston 30
Helsinki 29
Woodbridge 29
Seoul 27
Boardman 26
Bologna 26
Seattle 25
Wilmington 25
Council Bluffs 24
New York 23
Cambridge 22
Lomé 22
Milan 22
Hyderabad 21
Munich 21
Lauterbourg 20
Ann Arbor 17
Redmond 15
Nanjing 14
Buffalo 13
Frankfurt am Main 13
São Paulo 13
Tokyo 13
Bremen 12
Da Nang 12
Berlin 11
Amman 10
Westminster 10
Brussels 9
Haiphong 9
Bern 8
Chicago 8
Johannesburg 8
London 8
Nuremberg 8
Shanghai 8
Toronto 8
Turin 8
Warsaw 8
Des Moines 7
Jakarta 7
Sofia 7
Guangzhou 6
Orem 6
Phoenix 6
Redondo Beach 6
San Francisco 6
Shenyang 6
Amsterdam 5
Bengaluru 5
Boydton 5
City of London 5
Lappeenranta 5
Paris 5
Redwood City 5
Saint Petersburg 5
San Diego 5
Abeokuta 4
Biên Hòa 4
Brooklyn 4
Bình Phước 4
Changchun 4
Hải Dương 4
Migliarino 4
Montreal 4
Norwalk 4
Rome 4
Shijiazhuang 4
Stockholm 4
The Dalles 4
Vienna 4
Wayne 4
Wenzhou 4
Addis Ababa 3
Bari 3
Boston 3
Can Tho 3
Chennai 3
Dhaka 3
Ercolano 3
Falkenstein 3
Fuzhou 3
Totale 2.294
Salva come PNG Salva come JPEG
Nome #
Disease-specific derangement of circulating endocannabinoids and n-acylethanolamines in myeloproliferative neoplasms 229
Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients 226
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib 214
Circulating megakaryocyte and platelet microvesicles correlate with response to ruxolitinib and distinct disease severity in patients with myelofibrosis 198
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients 179
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis 159
Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib. 155
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome 153
The role of circulating monocytes and JAK inhibition in the infectious-driven inflammatory response of myelofibrosis 146
Understanding how older age drives decision-making and outcome in Immune Thrombocytopenia. A single centre study on 465 adult patients 145
Management of elderly patients with immune thrombocytopenia: Real-world evidence from 451 patients older than 60 years. 142
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis 140
Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data 136
Immune thrombotic thrombocytopenic purpura: Personalized therapy using ADAMTS-13 activity and autoantibodies 133
Second primary malignancy in myelofibrosis patients treated with ruxolitinib 129
The diagnostic role of next generation sequencing in uncovering isolated splenomegaly: A case report 129
Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosis 126
Real-world use of thrombopoietin receptor agonists in older patients with primary immune thrombocytopenia 124
Spleen and Liver Fibrosis Is Associated to Treatment Response and Prognosis in Philadelphia-Negative Chronic Myeloproliferative Neoplasms 121
Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib 118
Immune Thrombocytopenia Onset and Relapse During the COVID-19 Pandemic. A Monocenter Study 110
Telemedicine in patients with haematological diseases during the coronavirus disease 2019 (COVID-19) pandemic: selection criteria and patients’ satisfaction 107
Impact of comorbidities and body mass index on the outcome of polycythemia vera patients 97
Longer-term response to SARS-CoV-2 vaccine in MPN patients: Role of ruxolitinib and disease severity 93
Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study⁎ 88
Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome 88
null 68
Totale 3.753
Salva come PNG Salva come JPEG
Categoria #
all - tutte 12.406
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12.406
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202157 0 0 0 0 0 0 0 0 0 0 0 57
2021/2022349 5 13 13 33 25 18 8 32 16 31 91 64
2022/2023478 35 58 30 63 44 48 12 28 97 14 26 23
2023/2024173 9 38 18 18 14 22 2 14 4 15 8 11
2024/2025667 59 59 59 64 70 34 42 48 8 63 43 118
2025/20261.657 149 122 150 119 164 94 161 99 387 123 40 49
Totale 3.753